Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5266393
Max Phase: Preclinical
Molecular Formula: C21H24N2O5S
Molecular Weight: 416.50
Associated Items:
ID: ALA5266393
Max Phase: Preclinical
Molecular Formula: C21H24N2O5S
Molecular Weight: 416.50
Associated Items:
Canonical SMILES: Cc1cccc(C2CCN(S(=O)(=O)c3ccc(C(=O)NCC(=O)O)cc3)CC2)c1
Standard InChI: InChI=1S/C21H24N2O5S/c1-15-3-2-4-18(13-15)16-9-11-23(12-10-16)29(27,28)19-7-5-17(6-8-19)21(26)22-14-20(24)25/h2-8,13,16H,9-12,14H2,1H3,(H,22,26)(H,24,25)
Standard InChI Key: WIDXQMUTTJMUFW-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 416.50 | Molecular Weight (Monoisotopic): 416.1406 | AlogP: 2.38 | #Rotatable Bonds: 6 |
Polar Surface Area: 103.78 | Molecular Species: ACID | HBA: 4 | HBD: 2 |
#RO5 Violations: 0 | HBA (Lipinski): 7 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 2.58 | CX Basic pKa: | CX LogP: 2.36 | CX LogD: -1.14 |
Aromatic Rings: 2 | Heavy Atoms: 29 | QED Weighted: 0.75 | Np Likeness Score: -1.39 |
1. Mann MK, Zepeda-Velázquez CA, González-Álvarez H, Dong A, Kiyota T, Aman AM, Loppnau P, Li Y, Wilson B, Arrowsmith CH, Al-Awar R, Harding RJ, Schapira M.. (2021) Structure-Activity Relationship of USP5 Inhibitors., 64 (20.0): [PMID:34648286] [10.1021/acs.jmedchem.1c00889] |
Source(1):